A newly developed targeted radiopharmaceutical treatment can effectively slow tumor growth in pancreatic ductal ...

The drug is available outside of a clinical trial for patients with metastatic PDAC who have had limited success with existing treatment options. The FDA has announced that it is expanding the use of ...

Despite ongoing efforts, outcomes among patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. Clinical trials are indispensable for therapeutic innovation, yet accrual among patients with ...

Approximately a third of patients with pancreatic ductal adenocarcinoma do not have elevated or detectable levels of a ...

Pancreatic cancer remains one of the deadliest malignancies, due in large part to challenges with early diagnosis.  Advanced ...

The annual Prospectors & Developers Association of Canada (PDAC) convention is returning this year from March 3 to 6, and it comes as countries around the world take steps to secure supply of key ...

In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated ...

The annual Prospectors & Developers Association of Canada (PDAC) convention is returning this year from March 1 to 4, and it comes at a significant time for the global resource sector. Precious metals ...